A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging
and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a
central role in regulating protein homeostasis. Hsp90 regulates the stability of key
proteins (called "client proteins") and keeps them in the appropriate three dimensional
shape so they can perform their cellular functions. In addition, many of the proteins
stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell
proliferation and cancer cell survival. Thus Hsp90, a single molecular target that is a
central integrator of multiple pathways important to cancer, is an ideal novel target for
oncologic therapy. Selective inhibition of Hsp90 will affect multiple downstream mechanisms
to disrupt tumor growth and selectively kill cancer cells. The anti-neoplastic effects of
Hsp90 inhibition have been demonstrated both in vitro and in vivo for a variety of different
hematologic and solid tumors including multiple myeloma.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety and maximum tolerated dose of IPI-504
Following 1 cycle of treatment
Yes
Sundar Jagannath, MD
Principal Investigator
St. Vincent's Comprehensive Cancer Center
United States: Food and Drug Administration
IPI-504-01
NCT00113204
June 2005
March 2007
Name | Location |
---|---|
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
St. Vincent's Comprehensive Cancer Center | New York, New York 10011 |
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland 21231 |
Hackensack University Medical Center The David Jurist Research Center | Hackensack, New Jersey 07601 |